Zynex Expands International Business Initiative

LONE TREE, Colo.--(BUSINESS WIRE)-- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announced the hiring of James Leffel as International Area Sales Manager.

In this position, Mr. Leffel, who has more than 25 years of sales and business development experience, will be responsible for establishing a market presence in Asia and the Middle East and supporting a network of distributors.

Thomas Sandgaard, CEO of Zynex stated; “Currently our international sales are not significant, as we have just begun to penetrate the global medical device marketplace, but we believe that considerable revenue opportunities exist. To date, we have engaged distributors in Canada, Australia, Philippines, Malaysia, Vietnam, UAE, Holland, and Germany. We are fortunate to have Mr. Leffel on board as our International Area Sales Manager for Asia and the Middle East, and look to build upon and accelerate our growth in international markets.”

Mr. Leffel previously led Zynex Medical’s NeuroMove sales efforts where he established product placement at some of the most prestigious physical rehab and spinal cord injury centers in the country including the Mayo Clinic, Mt. Sinai, Kessler, Rehabilitation Institute of Chicago (RIC), Kennedy Krieger International Spinal Cord Ctr., St. Johns Hospital, and John Hopkins. Mr. Leffel has also held senior level sales and marketing positions with Pentax USA and NPD Market Research Group. Mr. Leffel holds a BS degree in Social Science from Carroll College in Montana.

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of medical devices in three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use, Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals and Zynex NeuroDiagnostic develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets. Zynex Medical's product line is fully developed, FDA-cleared, commercially sold, and has been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostic are currently both in the development stages without any significant revenues. For additional information, please visit: http://www.ir-site.com/zynex/default.asp.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2009.

Zynex, Inc.Anthony Scalese, CFO, 303-703-4906

Source: Zynex, Inc.